{
  "_id": "NCT00104663",
  "title": "PRION-1: Quinacrine for Human Prion Disease",
  "text": "Summary: PRION-1 aims to assess the activity and safety of Quinacrine (Mepacrine hydrochloride) in human prion disease. It also aims to establish an appropriate framework for the clinical assessment of therapeutic options for human prion disease that can be refined or expanded in the future, as new agents become available.\nInclusion criteria: inclusion criteria: \n\n Aged 12 years or more, diagnosed with any type of human prion disease. \n\n \nExclusion criteria: : \n\n In a coma, or in a pre-terminal phase of disease such that prolongation of the current quality of life would not be supported \n\n Known sensitivity to quinacrine \n\n Been taking any other putative anti-prion therapy for less than 8 weeks",
  "metadata": {
    "brief_title": "PRION-1: Quinacrine for Human Prion Disease",
    "phase": "",
    "drugs": "['Quinacrine']",
    "drugs_list": [
      "Quinacrine"
    ],
    "diseases": "['Prion Disease']",
    "diseases_list": [
      "Prion Disease"
    ],
    "enrollment": "160.0",
    "inclusion_criteria": "inclusion criteria: \n\n Aged 12 years or more, diagnosed with any type of human prion disease. \n\n ",
    "exclusion_criteria": ": \n\n In a coma, or in a pre-terminal phase of disease such that prolongation of the current quality of life would not be supported \n\n Known sensitivity to quinacrine \n\n Been taking any other putative anti-prion therapy for less than 8 weeks",
    "brief_summary": "PRION-1 aims to assess the activity and safety of Quinacrine (Mepacrine hydrochloride) in human prion disease. It also aims to establish an appropriate framework for the clinical assessment of therapeutic options for human prion disease that can be refined or expanded in the future, as new agents become available."
  }
}